Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer

Michael Atkins, Meredith Regan, David McDermott, James Mier, Eric Stanbridge, Amanda Youmans, Philip Febbo, Melissa Upton, Mirna Lechpammer, Sabina Signoretti

Research output: Contribution to journalArticle

360 Citations (Scopus)

Abstract

Purpose: Renal cancer response to interleukin 2 (IL-2) therapy and patient survival has been correlated with tumor histology and carbonic anhydrase IX (CAIX) expression. In an effort to confirm and expand these observations, we examined CAIX expression in pathology specimens from renal cancer patients who had previously received IL-2 therapy. Experimental Design: Paraffin-embedded tissue sections of renal cancer were immunostained with the MN-75 monoclonal antibody to CAIX and expression levels were correlated with histologic findings and clinical outcome. Results: Tissue specimens were obtained from 66 patients; 27 of whom (41%) had responded to IL-2-based therapy. Fifty-eight specimens were assessed as clear cell, with 56, 33, and 4 having alveolar, granular, and papillary features, respectively. Twenty-four (36%), 31 (47%), and 11 (17%) were classified into good, intermediate, and poor prognosis groups according to the Upton pathology model. Forty-one specimens (62%) had high CAIX expression. Twenty-one of 27 (78%) responding patients had high CAIX expressing tumors compared with 20 of 39 (51%) non-responders (odds ratio, 3.3; P = 0.04). Median survival was prolonged (P = 0.04) and survival >5 years was only seen in high CAIX expressers. In patients with intermediate pathologic prognosis, all nine responders had high CAIX expression versus 11 of 22 nonresponders. A resultant group with good pathologic prognosis alone or with intermediate pathologic prognosis and high CAIX contained 26 of 27 (96%) responders compared with 18 of 39 (46%) nonresponders (odds ratio, 30; P < 0.01) and exhibited longer median survival (P < 0.01). Conclusions: CAIX expression seems to be an important predictor of outcome in renal cell carcinoma patients receiving IL-2-based therapy and may enhance prognostic information obtained from pathology specimens.

Original languageEnglish (US)
Pages (from-to)3714-3721
Number of pages8
JournalClinical Cancer Research
Volume11
Issue number10
DOIs
StatePublished - May 15 2005
Externally publishedYes

Fingerprint

Kidney Neoplasms
Interleukin-2
Therapeutics
Survival
Pathology
Odds Ratio
Carbonic Anhydrase IX
Renal Cell Carcinoma
Paraffin
Neoplasms
Histology
Research Design
Monoclonal Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Atkins, M., Regan, M., McDermott, D., Mier, J., Stanbridge, E., Youmans, A., ... Signoretti, S. (2005). Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clinical Cancer Research, 11(10), 3714-3721. https://doi.org/10.1158/1078-0432.CCR-04-2019

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. / Atkins, Michael; Regan, Meredith; McDermott, David; Mier, James; Stanbridge, Eric; Youmans, Amanda; Febbo, Philip; Upton, Melissa; Lechpammer, Mirna; Signoretti, Sabina.

In: Clinical Cancer Research, Vol. 11, No. 10, 15.05.2005, p. 3714-3721.

Research output: Contribution to journalArticle

Atkins, M, Regan, M, McDermott, D, Mier, J, Stanbridge, E, Youmans, A, Febbo, P, Upton, M, Lechpammer, M & Signoretti, S 2005, 'Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer', Clinical Cancer Research, vol. 11, no. 10, pp. 3714-3721. https://doi.org/10.1158/1078-0432.CCR-04-2019
Atkins, Michael ; Regan, Meredith ; McDermott, David ; Mier, James ; Stanbridge, Eric ; Youmans, Amanda ; Febbo, Philip ; Upton, Melissa ; Lechpammer, Mirna ; Signoretti, Sabina. / Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 10. pp. 3714-3721.
@article{23ea2746e0704e61b4d186cdac2e53e0,
title = "Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer",
abstract = "Purpose: Renal cancer response to interleukin 2 (IL-2) therapy and patient survival has been correlated with tumor histology and carbonic anhydrase IX (CAIX) expression. In an effort to confirm and expand these observations, we examined CAIX expression in pathology specimens from renal cancer patients who had previously received IL-2 therapy. Experimental Design: Paraffin-embedded tissue sections of renal cancer were immunostained with the MN-75 monoclonal antibody to CAIX and expression levels were correlated with histologic findings and clinical outcome. Results: Tissue specimens were obtained from 66 patients; 27 of whom (41{\%}) had responded to IL-2-based therapy. Fifty-eight specimens were assessed as clear cell, with 56, 33, and 4 having alveolar, granular, and papillary features, respectively. Twenty-four (36{\%}), 31 (47{\%}), and 11 (17{\%}) were classified into good, intermediate, and poor prognosis groups according to the Upton pathology model. Forty-one specimens (62{\%}) had high CAIX expression. Twenty-one of 27 (78{\%}) responding patients had high CAIX expressing tumors compared with 20 of 39 (51{\%}) non-responders (odds ratio, 3.3; P = 0.04). Median survival was prolonged (P = 0.04) and survival >5 years was only seen in high CAIX expressers. In patients with intermediate pathologic prognosis, all nine responders had high CAIX expression versus 11 of 22 nonresponders. A resultant group with good pathologic prognosis alone or with intermediate pathologic prognosis and high CAIX contained 26 of 27 (96{\%}) responders compared with 18 of 39 (46{\%}) nonresponders (odds ratio, 30; P < 0.01) and exhibited longer median survival (P < 0.01). Conclusions: CAIX expression seems to be an important predictor of outcome in renal cell carcinoma patients receiving IL-2-based therapy and may enhance prognostic information obtained from pathology specimens.",
author = "Michael Atkins and Meredith Regan and David McDermott and James Mier and Eric Stanbridge and Amanda Youmans and Philip Febbo and Melissa Upton and Mirna Lechpammer and Sabina Signoretti",
year = "2005",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-04-2019",
language = "English (US)",
volume = "11",
pages = "3714--3721",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer

AU - Atkins, Michael

AU - Regan, Meredith

AU - McDermott, David

AU - Mier, James

AU - Stanbridge, Eric

AU - Youmans, Amanda

AU - Febbo, Philip

AU - Upton, Melissa

AU - Lechpammer, Mirna

AU - Signoretti, Sabina

PY - 2005/5/15

Y1 - 2005/5/15

N2 - Purpose: Renal cancer response to interleukin 2 (IL-2) therapy and patient survival has been correlated with tumor histology and carbonic anhydrase IX (CAIX) expression. In an effort to confirm and expand these observations, we examined CAIX expression in pathology specimens from renal cancer patients who had previously received IL-2 therapy. Experimental Design: Paraffin-embedded tissue sections of renal cancer were immunostained with the MN-75 monoclonal antibody to CAIX and expression levels were correlated with histologic findings and clinical outcome. Results: Tissue specimens were obtained from 66 patients; 27 of whom (41%) had responded to IL-2-based therapy. Fifty-eight specimens were assessed as clear cell, with 56, 33, and 4 having alveolar, granular, and papillary features, respectively. Twenty-four (36%), 31 (47%), and 11 (17%) were classified into good, intermediate, and poor prognosis groups according to the Upton pathology model. Forty-one specimens (62%) had high CAIX expression. Twenty-one of 27 (78%) responding patients had high CAIX expressing tumors compared with 20 of 39 (51%) non-responders (odds ratio, 3.3; P = 0.04). Median survival was prolonged (P = 0.04) and survival >5 years was only seen in high CAIX expressers. In patients with intermediate pathologic prognosis, all nine responders had high CAIX expression versus 11 of 22 nonresponders. A resultant group with good pathologic prognosis alone or with intermediate pathologic prognosis and high CAIX contained 26 of 27 (96%) responders compared with 18 of 39 (46%) nonresponders (odds ratio, 30; P < 0.01) and exhibited longer median survival (P < 0.01). Conclusions: CAIX expression seems to be an important predictor of outcome in renal cell carcinoma patients receiving IL-2-based therapy and may enhance prognostic information obtained from pathology specimens.

AB - Purpose: Renal cancer response to interleukin 2 (IL-2) therapy and patient survival has been correlated with tumor histology and carbonic anhydrase IX (CAIX) expression. In an effort to confirm and expand these observations, we examined CAIX expression in pathology specimens from renal cancer patients who had previously received IL-2 therapy. Experimental Design: Paraffin-embedded tissue sections of renal cancer were immunostained with the MN-75 monoclonal antibody to CAIX and expression levels were correlated with histologic findings and clinical outcome. Results: Tissue specimens were obtained from 66 patients; 27 of whom (41%) had responded to IL-2-based therapy. Fifty-eight specimens were assessed as clear cell, with 56, 33, and 4 having alveolar, granular, and papillary features, respectively. Twenty-four (36%), 31 (47%), and 11 (17%) were classified into good, intermediate, and poor prognosis groups according to the Upton pathology model. Forty-one specimens (62%) had high CAIX expression. Twenty-one of 27 (78%) responding patients had high CAIX expressing tumors compared with 20 of 39 (51%) non-responders (odds ratio, 3.3; P = 0.04). Median survival was prolonged (P = 0.04) and survival >5 years was only seen in high CAIX expressers. In patients with intermediate pathologic prognosis, all nine responders had high CAIX expression versus 11 of 22 nonresponders. A resultant group with good pathologic prognosis alone or with intermediate pathologic prognosis and high CAIX contained 26 of 27 (96%) responders compared with 18 of 39 (46%) nonresponders (odds ratio, 30; P < 0.01) and exhibited longer median survival (P < 0.01). Conclusions: CAIX expression seems to be an important predictor of outcome in renal cell carcinoma patients receiving IL-2-based therapy and may enhance prognostic information obtained from pathology specimens.

UR - http://www.scopus.com/inward/record.url?scp=21044442672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044442672&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-2019

DO - 10.1158/1078-0432.CCR-04-2019

M3 - Article

C2 - 15897568

AN - SCOPUS:21044442672

VL - 11

SP - 3714

EP - 3721

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -